title: Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trial.
authors.affiliation: Wayne State University Medical Center, Detroit, MI.
authors.forename: L E
authors.initials: LE
authors.lastname: Flaherty
authors.forename: P Y
authors.initials: PY
authors.lastname: Liu
authors.forename: W S
authors.initials: WS
authors.lastname: Fletcher
authors.forename: J W
authors.initials: JW
authors.lastname: Goodwin
authors.forename: S P
authors.initials: SP
authors.lastname: Balcerzak
authors.forename: D
authors.initials: D
authors.lastname: Daniels
authors.forename: R L
authors.initials: RL
authors.lastname: Stephens
authors.forename: V K
authors.initials: VK
authors.lastname: Sondak
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use / Q000633:toxicity*; D003606:Dacarbazine / Q000008:administration & dosage / Q000633:toxicity*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000633:toxicity*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D010045:Outpatients; D012727:Sex Characteristics
chemical_list: D007376:Interleukin-2; D003606:Dacarbazine